Bojena Bitman

SFBN Feed: OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate https://lnkd.in/gZFRtEjw DALLAS–(BUSINESS WIRE)–OncoNano Medicine, Inc. (“OncoNano”) today announced a research collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) (“Gilead”) to evaluate OncoNano’s ON-BOARD™ encapsulation technology with Gilead’s drug candidate. Under the terms of the agreement, OncoNano and [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

17

2 Comments

SFBN Trending News: OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate https://lnkd.in/gqAR7N2n DALLAS–(BUSINESS WIRE)–OncoNano Medicine, Inc. (“OncoNano”) today announced a research collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) (“Gilead”) to evaluate OncoNano’s ON-BOARD encapsulation technology with Gilead’s drug candidate. Under the terms of the agreement, OncoNano and [...]

2

Inside the Single-Cell Revolution: One Biosciences Path to Clinical Reality - Wissam Hamou Ph.D, COO In this episode of DiagnosingDx, I’m joined by Wissam Hamou, Chief Operating Officer of One Biosciences, a company bringing single-cell diagnostics out of the lab and into real clinical practice.   We explore why single-cell analysis is finally ready for the clinic, how AI is unlocking insights that were previously impossible to see, and what this technology means for trials, treatment response, and the future of precision medicine.   🔥 Key Takeaways: 🔹 Single-cell technology is advancing toward real clinical validation, backed by fresh Series A funding. 🔹 AI is essential for making sense of the complex and high-dimensional data single-cell methods produce. 🔹 Cost, trust, and education remain key barriers to adoption among clinicians. 🔹 Regulatory clarity is urgently needed to establish standardized guidelines for single-cell assays. 🎧 Listen/watch now on: 🔹 YouTube: https://lnkd.in/eyMJN6yC 🔹 Spotify: https://lnkd.in/efNDNx3Z 🔹 Apple: https://lnkd.in/eRYnT_Yz 🔔 If you want to be alerted of new Diagnosing Dx episodes straight to your email inbox sign up here: https://lnkd.in/eQ4cebZv

17

Important data release on givastomig as a bolt-on to SOC of front line metastatic gastric cancer: well tolerated with 71% ORR and the lowest claudin expression cut off. More to come in the future!

48

4 Comments

New Qualified Treatment Center for ZEVASKYN in the SF Bay Area! Abeona Therapeutics has announced a new site in the San Francisco Bay Area is now qualified to administer ZEVASKYN, the first FDA-approved gene therapy for RDEB. • Learn more and see if you’re eligible: https://lnkd.in/g_nWwZnv • Read the press release: https://lnkd.in/gNMV6WWZ Support for travel, lodging, and care coordination may be available.

47

“Congruence Therapeutics’s advanced computational discovery engine is attracting growing global attention with its lead program entering clinical development. We are honored that our ongoing collaboration with Congruence is expanding beyond oncology to other priority areas including both neurology and immunology,” said Seishi Katsumata, Corporate Officer / Executive Director, Discovery & Research of ONO PHARMACEUTICAL CO., LTD.. “Through this partnership, we will be committed to accelerating the drug development so that we can deliver innovative new medicines to patients with unmet medical needs as quickly as possible.” #DrugDiscovery #Biopharma #BiotechInnovation #DrugDevelopment #NeurologyResearch #Immunology #PrecisionMedicine #LifeSciences #PharmaInnovation https://lnkd.in/dfYwX52A

18

At the TPD & Induced Proximity Summit today, Halda CMO Eyal Attar, MD, will present on how our RIPTAC™ therapeutics are designed to overcome the known bypass mechanisms of resistance. He will also share his expertise on a panel exploring how targeted protein degradation (TDP) is positioned to deliver transformative therapies for challenging diseases. #TPDSummit #TPD #TargetedProteinDegradation

137

1 Comment

As patents for key oncology biologics begin to expire, biosimilar developers are entering a pivotal moment of opportunity. The next wave of innovation, spanning ADC, BsAb, and CAR-T biosimilars, is set to reshape the competitive landscape. In her latest article, Kim Salgado from ICON explores: ✅ The evolving regulatory environment ✅ Strategic considerations for biosimilar development ✅ How biopharma companies can position themselves for success

8

SDBN Feed: Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44 https://lnkd.in/gR75_TRP SAN DIEGO, Nov. 19, 2025 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its Managed Access Program [...]

68

Additional positive results for CDK4/6 inhibitors in HR+/HER2- breast cancer. The new data shows significant improvement in overall survival (OS) and invasive disease-free survival (IDFS).

6

Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting https://lnkd.in/ghxp_kg8 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced interim data from its ongoing Phase 1/2 multidose study of VGA039 [...]

🧬 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗧𝗮𝗿𝗴𝗲𝘁 𝗨𝗽𝗱𝗮𝘁𝗲 𝗦𝗲𝗿𝗶𝗲𝘀 #𝟯: 𝗔𝗟𝗞 - 𝗧𝗵𝗲 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗦𝘂𝗿𝘃𝗶𝘃𝗮𝗹 𝗦𝘂𝗰𝗰𝗲𝘀𝘀 𝗦𝘁𝗼𝗿𝘆 Serving up the third in our series with ALK's incredible 2024-2025 achievements - from historic 5-year survival milestones to fourth-generation breakthroughs that are redefining what's possible in precision oncology! 🎯 𝗪𝗵𝗮𝘁'𝘀 𝗵𝗮𝗽𝗽𝗲𝗻𝗶𝗻𝗴 𝗿𝗶𝗴𝗵𝘁 𝗻𝗼𝘄: 🏆 𝙃𝙞𝙨𝙩𝙤𝙧𝙞𝙘 𝙨𝙪𝙧𝙫𝙞𝙫𝙖𝙡 𝙗𝙧𝙚𝙖𝙠𝙩𝙝𝙧𝙤𝙪𝙜𝙝 𝙖𝙘𝙝𝙞𝙚𝙫𝙚𝙙:  • 60% of patients progression-free at 5 years (lorlatinib CROWN study)  • First adjuvant ALK inhibitor approved (76% recurrence reduction)  • Near-normal life expectancy now achievable for many patients 🔬 𝙁𝙤𝙪𝙧𝙩𝙝-𝙜𝙚𝙣𝙚𝙧𝙖𝙩𝙞𝙤𝙣 𝙞𝙣𝙝𝙞𝙗𝙞𝙩𝙤𝙧𝙨 𝙘𝙤𝙣𝙦𝙪𝙚𝙧 𝙧𝙚𝙨𝙞𝙨𝙩𝙖𝙣𝙘𝙚: • NVL-655 gets FDA Breakthrough Therapy Designation (May 2024) • 69% response rate in G1202R resistant patients • TPX-0131 achieves 96% CNS penetration for brain mets 💊 𝙈𝙖𝙧𝙠𝙚𝙩 𝙚𝙭𝙥𝙖𝙣𝙨𝙞𝙤𝙣 𝙗𝙚𝙮𝙤𝙣𝙙 𝙡𝙪𝙣𝙜 𝙘𝙖𝙣𝙘𝙚𝙧: • 63% response rates in paediatric neuroblastoma (Phase 3 trials launching 2025) • ALK-positive inflammatory myofibroblastic tumors showing responses • Pan-cancer ALK approach gaining momentum 💰 𝘾𝙤𝙢𝙢𝙚𝙧𝙘𝙞𝙖𝙡 𝙫𝙖𝙡𝙞𝙙𝙖𝙩𝙞𝙤𝙣 𝙘𝙤𝙣𝙩𝙞𝙣𝙪𝙚𝙨: • Roche's Alecensa: $1.28B revenue in 2024 • Total ALK market approaches $2B across major players • PDX model market grew 12.33% driven by ALK applications 🔬 𝘼𝙙𝙫𝙖𝙣𝙘𝙚𝙙 𝙢𝙤𝙙𝙚𝙡𝙨 𝙖𝙘𝙘𝙚𝙡𝙚𝙧𝙖𝙩𝙚 𝙙𝙞𝙨𝙘𝙤𝙫𝙚𝙧𝙮: • 87% organoid establishment success from malignant effusions • Drug sensitivity testing completed in 7-10 days • Patient-derived models show 85% liquid biopsy correlation ⚡ 𝙉𝙤𝙫𝙚𝙡 𝙖𝙥𝙥𝙧𝙤𝙖𝙘𝙝𝙚𝙨 𝙚𝙢𝙚𝙧𝙜𝙚: • PROTAC-based ALK degraders entering clinic • Combination strategies with immunotherapy advancing • ADCs showing 23.5% response rates in resistant disease 💡 𝗪𝗵𝘆 𝘁𝗵𝗶𝘀 𝗺𝗮𝘁𝘁𝗲𝗿𝘀 𝗳𝗼𝗿 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁: ALK exemplifies precision oncology at its best - from palliative first-generation drugs to curative adjuvant applications with 5-year survival milestones. The key? 𝗦𝗼𝗽𝗵𝗶𝘀𝘁𝗶𝗰𝗮𝘁𝗲𝗱 𝗽𝗮𝘁𝗶𝗲𝗻𝘁-𝗱𝗲𝗿𝗶𝘃𝗲𝗱 𝗺𝗼𝗱𝗲𝗹𝘀 𝘁𝗵𝗮𝘁 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝘆 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗲 𝘁𝗼 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘀𝘂𝗰𝗰𝗲𝘀𝘀. Fourth-generation agents targeting compound resistance prove that even the most challenging mutations can be conquered with the right preclinical foundation. 𝘞𝘩𝘢𝘵'𝘴 𝘮𝘰𝘴𝘵 𝘪𝘮𝘱𝘳𝘦𝘴𝘴𝘪𝘷𝘦 𝘢𝘣𝘰𝘶𝘵 𝘈𝘓𝘒'𝘴 𝘱𝘳𝘦𝘤𝘪𝘴𝘪𝘰𝘯 𝘰𝘯𝘤𝘰𝘭𝘰𝘨𝘺 𝘫𝘰𝘶𝘳𝘯𝘦𝘺? 𝘏𝘰𝘸 𝘢𝘳𝘦 𝘺𝘰𝘶 𝘭𝘦𝘷𝘦𝘳𝘢𝘨𝘪𝘯𝘨 𝘢𝘥𝘷𝘢𝘯𝘤𝘦𝘥 𝘮𝘰𝘥𝘦𝘭𝘴 𝘪𝘯 𝘺𝘰𝘶𝘳 𝘥𝘳𝘶𝘨 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵? 𝘕𝘦𝘹𝘵 𝘶𝘱: 𝘉𝘙𝘈𝘍 𝘵𝘢𝘳𝘨𝘦𝘵 𝘶𝘱𝘥𝘢𝘵𝘦! #ALK #PrecisionOncology #DrugDiscovery #Oncology #Biotech #OncologyTargets #NSCLC #Neuroblastoma

6

We are excited to be presenting preclinical data on the first known BTK SH2 domain inhibitor (BTK SH2i) at #SIDSanDiego25! A BTK SH2i is an attractive therapeutic approach for B cell and mast cell-mediated inflammatory diseases, such as chronic spontaneous urticaria (CSU) and multiple sclerosis. We showed its potent BTK inhibition reduced skin inflammation in a model of CSU, and its high selectivity for BTK is differentiated compared to other approaches to inhibit BTK. These data are outlined in today’s press release: https://lnkd.in/eNFnx7eQ

90

1 Comment